Amy O. Johnson‐Levonas

3.2k total citations
89 papers, 2.4k citations indexed

About

Amy O. Johnson‐Levonas is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Amy O. Johnson‐Levonas has authored 89 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Surgery, 31 papers in Endocrinology, Diabetes and Metabolism and 17 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Amy O. Johnson‐Levonas's work include Lipoproteins and Cardiovascular Health (37 papers), Cancer, Lipids, and Metabolism (15 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (15 papers). Amy O. Johnson‐Levonas is often cited by papers focused on Lipoproteins and Cardiovascular Health (37 papers), Cancer, Lipids, and Metabolism (15 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (15 papers). Amy O. Johnson‐Levonas collaborates with scholars based in United States, Belgium and Canada. Amy O. Johnson‐Levonas's co-authors include Teddy Kosoglou, Paul Statkevich, John F. Paolini, Arthur Bergman, Kevin B. Alton, Aditi Sapre, Keith D. Kaufman, Arvind Shah, Rachid Massaad and John A. Wagner and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and PEDIATRICS.

In The Last Decade

Amy O. Johnson‐Levonas

89 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amy O. Johnson‐Levonas United States	28	1.3k	801	416	349	344	89	2.4k
Sukrut Shah United States	25	2.0k 1.6×	1.0k 1.3×	555 1.3×	500 1.4×	341 1.0×	61	3.5k
Phillip D. Toth United States	11	1.3k 1.0×	586 0.7×	254 0.6×	119 0.3×	231 0.7×	25	1.8k
Gunnar Fager Sweden	31	1.1k 0.8×	759 0.9×	441 1.1×	692 2.0×	859 2.5×	62	3.1k
Min‐Ji Charng Taiwan	16	883 0.7×	522 0.7×	334 0.8×	486 1.4×	582 1.7×	40	2.3k
Antonio González‐Pérez Spain	27	678 0.5×	249 0.3×	211 0.5×	366 1.0×	618 1.8×	69	2.8k
Claude Gagné Canada	34	2.6k 2.1×	1.9k 2.3×	858 2.1×	463 1.3×	1.1k 3.3×	77	4.0k
Sidney Rosenblatt United States	11	383 0.3×	676 0.8×	96 0.2×	472 1.4×	148 0.4×	13	1.3k
M.J. Whiting Australia	20	1.6k 1.3×	1.7k 2.1×	329 0.8×	948 2.7×	733 2.1×	39	3.7k
Stuart Weiss United States	22	1.9k 1.5×	1.3k 1.6×	333 0.8×	1.3k 3.7×	332 1.0×	28	5.8k
Eric J. Stanek United States	19	724 0.6×	477 0.6×	195 0.5×	209 0.6×	609 1.8×	58	2.1k

Countries citing papers authored by Amy O. Johnson‐Levonas

Since Specialization

Citations

This map shows the geographic impact of Amy O. Johnson‐Levonas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy O. Johnson‐Levonas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy O. Johnson‐Levonas more than expected).

Fields of papers citing papers by Amy O. Johnson‐Levonas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy O. Johnson‐Levonas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy O. Johnson‐Levonas. The network helps show where Amy O. Johnson‐Levonas may publish in the future.

Co-authorship network of co-authors of Amy O. Johnson‐Levonas

This figure shows the co-authorship network connecting the top 25 collaborators of Amy O. Johnson‐Levonas. A scholar is included among the top collaborators of Amy O. Johnson‐Levonas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy O. Johnson‐Levonas. Amy O. Johnson‐Levonas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ballantyne, Christie M., Sukrut Shah, Aditi Sapre, et al.. (2017). A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol. The American Journal of Cardiology. 120(4). 569–576. 9 indexed citations

Teramoto, Tamio, Hiroyuki Daida, Katsunori Ikewaki, et al.. (2017). Lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in Japanese patients with dyslipidemia. Atherosclerosis. 261. 69–77. 9 indexed citations

Ballantyne, Christie M., Sukrut Shah, Uma Kher, et al.. (2016). Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol. The American Journal of Cardiology. 119(3). 388–396. 12 indexed citations

Ravandi, Farhad, Ivana Gojo, Mrinal M. Patnaik, et al.. (2016). A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML). Leukemia Research. 48. 92–100. 48 indexed citations

Brinton, Eliot A., Joseph Triscari, Philippe Brudi, et al.. (2016). Effects of extended-release niacin/laropiprant on correlations between apolipoprotein B, LDL-cholesterol and non-HDL-cholesterol in patients with type 2 diabetes. Lipids in Health and Disease. 15(1). 116–116. 3 indexed citations

Anderson, Matt S., Josée Côté, Yang Liu, et al.. (2013). Effects of Rifampin, a Potent Inducer of Drug‐Metabolizing Enzymes and an Inhibitor of OATP1B1/3 Transport, on the Single Dose Pharmacokinetics of Anacetrapib. The Journal of Clinical Pharmacology. 53(7). 746–752. 14 indexed citations

Farnier, Michel, John R. Guyton, Erin Jensen, et al.. (2013). Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia. Atherosclerosis. 229(2). 415–422. 12 indexed citations

Fonseca, Vivian, Bart Staels, Yue Shentu, et al.. (2012). Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes. Journal of Diabetes and its Complications. 27(2). 177–183. 45 indexed citations

Wagner, Frank, Marie‐Pierre Malice, Erol Wiegert, et al.. (2012). A comparison of the natriuretic and kaliuretic effects of cicletanine and hydrochlorothiazide in prehypertensive and hypertensive humans. Journal of Hypertension. 30(4). 819–827. 11 indexed citations

10.

Krauss, Ronald M., Cathy Anne Pinto, Yang Liu, et al.. (2011). Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib. Journal of Lipid Research. 53(3). 540–547. 69 indexed citations

11.

Guyton, John R., D. J. Betteridge, Michel Farnier, et al.. (2011). Achievement of recommended lipid and lipoprotein levels with combined ezetimibe/statin therapy versus statin alone in patients with and without diabetes. Diabetes and Vascular Disease Research. 8(2). 160–172. 18 indexed citations

12.

Radziszewski, Waldemar, Eseng Lai, Mark Stroh, et al.. (2010). A Single Supratherapeutic Dose of Rolofylline Does Not Prolong the QTcF Interval in Healthy Volunteers. American Journal of Therapeutics. 17(1). 8–16. 1 indexed citations

13.

Gargano, Cynthia, Alice Jackson, Chan Beals, et al.. (2010). An enhanced bunionectomy model as a potential tool for early decision-making in the development of new analgesics. Advances in Therapy. 27(12). 963–980. 22 indexed citations

14.

Proietto, Joseph, A Rissanen, Joyce B. Harp, et al.. (2010). A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study. International Journal of Obesity. 34(8). 1243–1254. 59 indexed citations

15.

Kipnes, Mark, Priscilla Hollander, Ken Fujioka, et al.. (2009). A one‐year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes. Diabetes Obesity and Metabolism. 12(6). 517–531. 43 indexed citations

16.

Schwartz, Jules I., Fang Liu, Mark Stroh, et al.. (2009). Influence of Laropiprant, a Selective Prostaglandin D2 Receptor 1 Antagonist, on the Pharmacokinetics and Pharmacodynamics of Warfarin. American Journal of Therapeutics. 16(3). 215–223. 4 indexed citations

17.

Feldman, Theodore, Leiv Ose, Arvind Shah, et al.. (2007). Efficacy and Safety of Ezetimibe/Simvastatin Versus Simvastatin Monotherapy in Hypercholesterolemic Patients with Metabolic Syndrome. Metabolic Syndrome and Related Disorders. 5(1). 13–21. 6 indexed citations

18.

Decochez, Katelijn, Jutta Miller, Marina De Smet, et al.. (2006). A Dual PPAR ??/?? Agonist Increases Adiponectin and Improves Plasma Lipid Profiles in Healthy Subjects. Drugs in R&D. 7(2). 99–110. 16 indexed citations

19.

Bedarida, Gabriella, et al.. (2005). Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease. International Journal of Clinical Practice. 59(6). 619–627. 42 indexed citations

20.

Bergman, Arthur, Amy O. Johnson‐Levonas, Joanne Burke, et al.. (2005). Assessment of pharmacokinetic interactions between ezetimibe and cyclosporine. Clinical Pharmacology & Therapeutics. 77(2). P75–P75. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact